1. Home
  2. NRSN vs LGCL Comparison

NRSN vs LGCL Comparison

Compare NRSN & LGCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • LGCL
  • Stock Information
  • Founded
  • NRSN 2017
  • LGCL 2009
  • Country
  • NRSN Israel
  • LGCL China
  • Employees
  • NRSN N/A
  • LGCL N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • LGCL
  • Sector
  • NRSN Health Care
  • LGCL
  • Exchange
  • NRSN Nasdaq
  • LGCL NYSE
  • Market Cap
  • NRSN 37.9M
  • LGCL 39.7M
  • IPO Year
  • NRSN 2021
  • LGCL 2024
  • Fundamental
  • Price
  • NRSN $1.79
  • LGCL $0.63
  • Analyst Decision
  • NRSN Buy
  • LGCL
  • Analyst Count
  • NRSN 2
  • LGCL 0
  • Target Price
  • NRSN $14.00
  • LGCL N/A
  • AVG Volume (30 Days)
  • NRSN 297.9K
  • LGCL 92.2K
  • Earning Date
  • NRSN 06-23-2025
  • LGCL 01-01-0001
  • Dividend Yield
  • NRSN N/A
  • LGCL N/A
  • EPS Growth
  • NRSN N/A
  • LGCL N/A
  • EPS
  • NRSN N/A
  • LGCL 0.07
  • Revenue
  • NRSN N/A
  • LGCL $145,690,427.00
  • Revenue This Year
  • NRSN N/A
  • LGCL N/A
  • Revenue Next Year
  • NRSN N/A
  • LGCL N/A
  • P/E Ratio
  • NRSN N/A
  • LGCL $9.15
  • Revenue Growth
  • NRSN N/A
  • LGCL N/A
  • 52 Week Low
  • NRSN $0.51
  • LGCL $0.28
  • 52 Week High
  • NRSN $1.80
  • LGCL $3.31
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 73.77
  • LGCL N/A
  • Support Level
  • NRSN $1.65
  • LGCL N/A
  • Resistance Level
  • NRSN $1.77
  • LGCL N/A
  • Average True Range (ATR)
  • NRSN 0.14
  • LGCL 0.00
  • MACD
  • NRSN 0.02
  • LGCL 0.00
  • Stochastic Oscillator
  • NRSN 100.00
  • LGCL 0.00

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.

Share on Social Networks: